Sanofi: positive results in NEJM
(CercleFinance.com) - Sanofi reports the publication, in the New England Journal of Medicine (NEJM), of positive final results of a phase I/IIA study that assessed the safety, tolerance and pharmacokinetics profiles of BIVV001 in adults with severe haemophilia A.
BIVV001 is an experimental replacement factor VIII designed to extend bleeding protection from a weekly prophylactic dose. Sanofi and Sobi are collaborating in its development and marketing.
"Results from the Phase 1/2a study showed that a single dose of BIVV001 achieved high sustained factor activity and a three- to four-fold increase in half-life when compared to conventional factor VIII replacement therapies," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
BIVV001 is an experimental replacement factor VIII designed to extend bleeding protection from a weekly prophylactic dose. Sanofi and Sobi are collaborating in its development and marketing.
"Results from the Phase 1/2a study showed that a single dose of BIVV001 achieved high sustained factor activity and a three- to four-fold increase in half-life when compared to conventional factor VIII replacement therapies," Sanofi said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.